Harnessing Chaperones to Generate Small-Molecule Inhibitors of Amyloid ß Aggregation
暂无分享,去创建一个
[1] Andrzej Galat,et al. Molecular cloning and overexpression of the human FK506-binding protein FKBP , 1990, Nature.
[2] J. Hardy,et al. The Amyloid Hypothesis of Alzheimer ’ s Disease : Progress and Problems on the Road to Therapeutics , 2009 .
[3] D. Westaway,et al. Transgenic mouse models of Alzheimer's disease. , 2000, Biochimica et biophysica acta.
[4] J. Ashby. References and Notes , 1999 .
[5] K. Stankunas,et al. Conditional protein alleles using knockin mice and a chemical inducer of dimerization. , 2003, Molecular cell.
[6] Peter T. Lansbury,et al. Carbon Nanotube Tips: High-Resolution Probes for Imaging Biological Systems , 1998 .
[7] K. Haldar,et al. A bifunctional molecule that displays context-dependent cellular activity. , 2003, Journal of the American Chemical Society.
[8] S. Schreiber,et al. Controlling signal transduction with synthetic ligands. , 1993, Science.
[9] M. Findeis,et al. Approaches to discovery and characterization of inhibitors of amyloid beta-peptide polymerization. , 2000, Biochimica et biophysica acta.
[10] T. Clackson,et al. Regulation of endogenous gene expression with a small-molecule dimerizer , 2002, Nature Biotechnology.
[11] L. Kiessling,et al. A Strategy for Designing Inhibitors of β-Amyloid Toxicity* , 1996, The Journal of Biological Chemistry.
[12] V. Lee,et al. Amyloid binding ligands as Alzheimer’s disease therapies , 2002, Neurobiology of Aging.
[13] M. Citron,et al. Emerging Alzheimer’s disease therapies: inhibition of β-secretase , 2002, Neurobiology of Aging.
[14] D. Selkoe,et al. Deciphering the genetic basis of Alzheimer's disease. , 2002, Annual review of genomics and human genetics.
[15] W. Klein. Aβ toxicity in Alzheimer’s disease: globular oligomers (ADDLs) as new vaccine and drug targets , 2002, Neurochemistry International.
[16] P. Lansbury,et al. Amyloid diseases: abnormal protein aggregation in neurodegeneration. , 1999, Proceedings of the National Academy of Sciences of the United States of America.
[17] Carl W. Cotman,et al. Common Structure of Soluble Amyloid Oligomers Implies Common Mechanism of Pathogenesis , 2003, Science.
[18] H. Levine. Quantification of beta-sheet amyloid fibril structures with thioflavin T. , 1999, Methods in enzymology.
[19] Peter T. Lansbury,et al. Assembly of Aβ Amyloid Protofibrils: An in Vitro Model for a Possible Early Event in Alzheimer's Disease† , 1999 .
[20] P. Lewi,et al. Protein–protein interactions: mechanisms and modification by drugs , 2002, Journal of molecular recognition : JMR.
[21] A. Mccarthy. Development , 1996, Current Opinion in Neurobiology.
[22] W. Delano,et al. Convergent solutions to binding at a protein-protein interface. , 2000, Science.
[23] 宁北芳,et al. 疟原虫var基因转换速率变化导致抗原变异[英]/Paul H, Robert P, Christodoulou Z, et al//Proc Natl Acad Sci U S A , 2005 .
[24] Andrzej Galat,et al. Peptidylprolyl cis/trans isomerases (immunophilins): biological diversity--targets--functions. , 2003, Current topics in medicinal chemistry.
[25] G. Crabtree,et al. Affinity modulation of small-molecule ligands by borrowing endogenous protein surfaces. , 1999, Proceedings of the National Academy of Sciences of the United States of America.
[26] Fred E. Cohen,et al. Therapeutic approaches to protein-misfolding diseases , 2003, Nature.
[27] James C. Sacchettini,et al. Therapeutic strategies for human amyloid diseases , 2002, Nature Reviews Drug Discovery.
[28] F. Young. Biochemistry , 1955, The Indian Medical Gazette.
[29] Jon Clardy,et al. DESIGN, SYNTHESIS, AND KINETIC EVALUATION OF HIGH-AFFINITY FKBP LIGANDS AND THE X-RAY CRYSTAL-STRUCTURES OF THEIR COMPLEXES WITH FKBP12. , 1994 .
[30] M. Michaelis. Drugs Targeting Alzheimer's Disease: Some Things Old and Some Things New , 2003, Journal of Pharmacology and Experimental Therapeutics.